Recent 8-K filings for CAMP

• August 4, 2026, 7:10 AM ET other material materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01

  CAMP4 Therapeutics closes second tranche of $100M private placement, raising $50.1M

  Second closing gross proceeds $50.1M from 10.76M shares at $1.53 and 21.93M pre-funded warrants at $1.5299.

• July 27, 2026, 7:01 AM ET regulatory materiality 0.85 positive item 7.01item 8.01item 9.01

  CAMP4 receives Australian TGA clearance for CMP-002 Phase 1/2 trial; triggers $50M second closing

  TGA and HREC clearance to initiate first-in-human Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder.

• May 14, 2026, 9:01 AM ET other material materiality 0.70 positive item 7.01item 9.01

  CAMP4 Therapeutics reports preclinical data showing CMP-002 improves seizure threshold in SYNGAP1 model

  CMP-002 produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mice.

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  CAMP4 Therapeutics reports Q1 net loss $18.3M; files first CMP-002 regulatory submission in Australia

  Cash and equivalents $99.2M as of 3/31/26, down from $109.5M; runway expected into 2028.

• March 5, 2026, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  CAMP4 FY2025 net loss $80.4M; cash runway into 2028, GSK deal, SYNGAP1 progress

  Net loss of $80.4M in FY2025 vs $51.8M in FY2024, driven by $29.8M non-cash loss on derivative tranche liability.

• December 18, 2025, 6:59 PM ET other material materiality 0.60 negative item 1.01item 9.01 ◈ Material Agreements

  CAMP4 Therapeutics prices 5M share offering at $6.00, expects $28M net proceeds

  CAMP4 Therapeutics priced public offering of 5,000,000 shares of common stock at $6.00 per share.

• December 18, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  CAMP4 enters collaboration with GSK for ASO therapeutics; $17.5M upfront, up to $440M milestones

  Collaboration with GSK to discover ASO therapeutics for neurodegenerative and kidney diseases using CAMP4's RAP Platform.

• November 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  CAMP4 Q3 net loss $15.1M, cash $75.3M; advances CMP-002 with up to $100M placement

  Cash, equivalents, and marketable securities $75.3M at Sept 30, up from $39.1M at June 30.

• October 1, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  CAMP4 initiates GLP toxicology studies for CMP-SYNGAP-01; Phase 1/2 target H2 2026

  Initiated GLP toxicology studies for CMP-SYNGAP-01, a regulatory RNA-targeting therapeutic for SYNGAP1-related disorders.

• September 10, 2025, 7:59 PM ET other material materiality 0.90 positive item 1.01item 3.02item 5.02item 7.01item 9.01 ◈ Equity Issuances ×3

  CAMP4 Therapeutics announces up to $100M private placement and board changes

  Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.

• August 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  CAMP4 reports Q2 net loss of $12.6M; cash $39.1M; pipeline advances in SYNGAP1 and UCD programs

  Net loss of $12.6M for Q2 2025, flat vs Q2 2024; R&D expenses $10.3M, G&A $4.2M.

• May 16, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  CAMP4 reports SYNGAP1 protein increase in NHPs and favorable Phase 1 safety data for UCD program at ASGCT

  CMP-SYNGAP-01 restored SYNGAP1 protein to near-normal in haploinsufficient mice and rescued motor/learning defects.

• May 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  CAMP4 Q1 net loss $12.4M; Phase 1 UCD data Q4 2025; SYNGAP1 candidate nominated

  Net loss of $12.4M for Q1 2025, flat YoY; cash, equivalents, and marketable securities $49.3M as of March 31, 2025.

• March 27, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  CAMP4 reports FY2024 net loss $51.8M; cash $64M, Phase 1 data expected Q4 2025

  Net loss of $51.8M for FY2024 vs $49.3M in FY2023; R&D expenses $38.8M, G&A $14.9M.

• January 7, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Camp4 Therapeutics reports positive Phase 1 SAD safety data for CMP-CPS-001, enables MAD dose escalation

  Phase 1 SAD portion completed: 48 healthy volunteers, 32 received CMP-CPS-001; no serious adverse events, no maximum tolerated dose reached.

• November 21, 2024, 6:59 PM ET other material materiality 0.80 positive item 2.02item 9.01

  CAMP4 reports Q3 net loss $13.5M, completes IPO raising $82.1M, and signs BioMarin collaboration

  Q3 net loss $13.5M vs $11.7M in prior year; R&D $9.7M, G&A $3.8M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

9 positive 1 negative 13 neutral

source · CAMP on sec.gov